| Identification | Back Directory | [Name]
5-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)methyl)thiazolidine-2,4-dione | [CAS]
213411-83-7 | [Synonyms]
R-483
Edaglitazone
EDAGLITAZONUM
RO-2052349-000
RO-2052349-602
5-[[4-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethoxy]benzo[b]thien-7-yl]methyl]-2,4-thiazolidinedione
2,4-Thiazolidinedione, 5-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzo[b]thien-7-yl]methyl]-
5-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)methyl)thiazolidine-2,4-dione | [Molecular Formula]
C24H20N2O4S2 | [MDL Number]
MFCD15529752 | [MOL File]
213411-83-7.mol | [Molecular Weight]
464.557 |
| Hazard Information | Back Directory | [Description]
Edaglitazone is an agonist of peroxisome proliferator-activated receptor γ (PPARγ). It activates PPARγ in a reporter assay using CV-1 cells expressing murine PPARγ2 when used at concentrations ranging from 0.1 to 1 μM. Edaglitazone (1, 5, and 25 μM) increases [3H]2-deoxyglucose transport in the presence and absence of insulin and increases glycogen synthesis in the presence of insulin in soleus muscle strips isolated from obese rats. | [Uses]
Edaglitazone possesses anti-diabetic properties and is a thiazolidinedione peroxisome proliferator-activated receptor gamma (PPARγ) agonist. Also, it is a cytochrome P 450 2C19 (CYP2C19) substrate. | [Uses]
Treatment of Type 2 diabetes. | [in vivo]
Edaglitazone (4.4 mg/kg; p.o. daily for 10 days) enhances insulin sensitivity in obese rats[2]. | [IC 50]
PPARγ: 35.6 nM (EC50); PPARα: 1053 nM (EC50) | [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
R&D Systems, Inc
|
| Tel: |
18003437475 18003437475 |
| Website: |
www.rndsystems.com |
|